• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用质量碎片谱法研究口服噻吗洛尔的药代动力学。

Pharmacokinetics of oral timolol studied by mass fragmentography.

作者信息

Fourtillan J B, Courtois P, Lefebvre M A, Girault J

出版信息

Eur J Clin Pharmacol. 1981 Feb;19(3):193-6. doi: 10.1007/BF00561948.

DOI:10.1007/BF00561948
PMID:7215417
Abstract

The pharmacokinetics of timolol, after oral administration of single 20 mg doses to healthy subjects, has been studied using an original electron beam ionization GLC-mass spectrometry technique with computer -- controlled multiple ion detection. This method of mass fragmentography, tested with propranolol as an internal standard, permitted the measurement of timolol concentrations as low as 1 ng/ml with good precision and accuracy. It enabled the plasma level to be followed up to the twelfth hour after treatment. Individual variation was observed in bioavailability; the peaks plasma concentration (Cmax) of 50 to 103 ng/ml being achieved at different times(0.5--3h). The residual level after 12 h differed greatly between the subjects (0.8 to 7.2 ng/ml). The mean half-life of the terminal elimination phase was 2.62 +/- 0.17 h. Extra-renal elimination (metabolic and biliary) represented the main route of elimination, with a renal to body clearance ratio of 0.123. This level paralleled the percentage of unaltered timolol excreted in urine 24 h after its administration.

摘要

对健康受试者单次口服20毫克剂量的噻吗洛尔后的药代动力学进行了研究,采用了一种原始的电子束电离气相色谱-质谱联用技术,并结合计算机控制的多离子检测。这种质量碎片分析法以普萘洛尔作为内标进行测试,能够精确测量低至1纳克/毫升的噻吗洛尔浓度。它能够追踪治疗后长达12小时的血浆水平。观察到生物利用度存在个体差异;在不同时间(0.5-3小时)达到的血浆峰值浓度(Cmax)为50至103纳克/毫升。12小时后的残留水平在受试者之间差异很大(0.8至7.2纳克/毫升)。终末消除相的平均半衰期为2.62±0.17小时。肾外消除(代谢和胆汁排泄)是主要的消除途径,肾清除率与全身清除率之比为0.123。这一水平与给药后24小时尿液中未改变的噻吗洛尔排泄百分比相当。

相似文献

1
Pharmacokinetics of oral timolol studied by mass fragmentography.采用质量碎片谱法研究口服噻吗洛尔的药代动力学。
Eur J Clin Pharmacol. 1981 Feb;19(3):193-6. doi: 10.1007/BF00561948.
2
Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
Clin Pharmacol Ther. 1982 Dec;32(6):676-85. doi: 10.1038/clpt.1982.223.
3
Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.
Eur J Clin Pharmacol. 1983;24(2):227-30. doi: 10.1007/BF00613822.
4
Mass fragmentographic determination of timolol in human plasma and urine.人血浆和尿液中噻吗洛尔的质量碎片分析法测定
J Pharm Sci. 1981 May;70(5):573-5. doi: 10.1002/jps.2600700529.
5
Absorption of ocular timolol.眼部噻吗洛尔的吸收
Clin Pharmacokinet. 1980 Jan-Feb;5(1):95-100. doi: 10.2165/00003088-198005010-00004.
6
Capillary column GLC-mass spectrometric assay with selected-ion monitoring for timolol and [13C3]timolol in human plasma.采用毛细管柱气相色谱-质谱联用仪,通过选择离子监测法测定人血浆中的噻吗洛尔和[13C3]噻吗洛尔。
J Pharm Sci. 1980 Oct;69(10):1111-5. doi: 10.1002/jps.2600691001.
7
Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals.
J Clin Pharmacol. 1978 Nov-Dec;18(11-12):511-8. doi: 10.1002/j.1552-4604.1978.tb01580.x.
8
Plasma timolol levels after oral and intravenous administration.
Eur J Clin Pharmacol. 1978 Dec 18;14(6):431-4. doi: 10.1007/BF00716385.
9
The disposition of timolol in man.噻吗洛尔在人体中的处置情况。
J Pharm Pharmacol. 1978 Jan;30(1):53-5. doi: 10.1111/j.2042-7158.1978.tb13155.x.
10
Pharmacokinetic differences between single and multiple oral dosing with the guidance for beta-adrenoceptor blockade assessment.
Cardiology. 1979;64 Suppl 1:25-43. doi: 10.1159/000170651.

引用本文的文献

1
The Role of Osteogenic Effect and Vascular Function in Bone Health in Hypertensive Rats: A Study of Anti-hypertensive and Hemorheologic Drugs.在高血压大鼠的骨骼健康中,成骨效应和血管功能的作用:抗高血压和血液流变学药物的研究。
Calcif Tissue Int. 2024 Mar;114(3):295-309. doi: 10.1007/s00223-023-01170-4. Epub 2023 Dec 15.
2
Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice.真皮基质、人间质干细胞和噻吗洛尔的组合产品可促进小鼠糖尿病伤口愈合。
Stem Cells Transl Med. 2020 Nov;9(11):1353-1364. doi: 10.1002/sctm.19-0380. Epub 2020 Jul 28.
3
Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

本文引用的文献

1
Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.对新型心脏选择性β-肾上腺素受体阻断药阿替洛尔(ICI 66,082)的人体药代动力学和药效学研究。
Br J Clin Pharmacol. 1976 Apr;3(2):267-72. doi: 10.1111/j.1365-2125.1976.tb00602.x.
2
Clinical pharmacokinetics of atenolol.阿替洛尔的临床药代动力学
Postgrad Med J. 1977;53 Suppl 3:74-8.
3
Acebutolol metabolite plasma concentration during chronic oral therapy.慢性口服治疗期间醋丁洛尔代谢物的血浆浓度
局部用噻吗洛尔引起的神经精神不良事件。
Clin Med Res. 2019 Dec;17(3-4):90-96. doi: 10.3121/cmr.2019.1486. Epub 2019 Aug 28.
4
Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life.青光眼患者使用0.1%噻吗洛尔的疗效、耐受性及生活质量
J Ophthalmol. 2019 May 2;2019:4146124. doi: 10.1155/2019/4146124. eCollection 2019.
5
The pharmacokinetics of timegadine and two of its metabolites after multiple oral dosing, and the effects of concomitant administration of ibuprofen.
Eur J Clin Pharmacol. 1986;29(5):581-6. doi: 10.1007/BF00635896.
Br J Clin Pharmacol. 1977 Oct;4(5):519-22. doi: 10.1111/j.1365-2125.1977.tb00779.x.
4
IGPHARM: interactive graphic package for pharmacokinetic analysis.IGPHARM:用于药代动力学分析的交互式图形软件包。
Comput Biomed Res. 1978 Aug;11(4):345-61. doi: 10.1016/0010-4809(78)90017-4.
5
Plasma timolol levels after oral and intravenous administration.
Eur J Clin Pharmacol. 1978 Dec 18;14(6):431-4. doi: 10.1007/BF00716385.
6
Timolol kinetics in chronic renal insufficiency.慢性肾功能不全时噻吗洛尔的动力学
Clin Pharmacol Ther. 1978 May;23(5):606-15. doi: 10.1002/cpt1978235606.
7
Physiological disposition and metabolism of timolol in man and laboratory animals.噻吗洛尔在人和实验动物体内的生理处置与代谢
Drug Metab Dispos. 1975 Sep-Oct;3(5):361-70.
8
The disposition of timolol in man.噻吗洛尔在人体中的处置情况。
J Pharm Pharmacol. 1978 Jan;30(1):53-5. doi: 10.1111/j.2042-7158.1978.tb13155.x.